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Background: Long-term studies of smokers who switch to lower nicotine yield cigarettes have been identified by
the World Health Organization Study Group TobReg and the US Food and Drug Administration as one key area
where new knowledge is required to guide science based regulation. The limited number of long-term switching
studies have concluded that smokers who switch to lower nicotine yield cigarettes show evidence of partial
compensation. Since the European Union tobacco product directive of 2001 introduced tar and nicotine yield
ceilings, there has been no long-term observational switching study. To address the limitations of previous studies
where smokers were forced switched for relatively short durations, we plan to undertake a long-term study of
spontaneous switching which is appropriately powered and includes non-switchers as a control group.
Methods/design: Healthy adult smokers aged 21–64 years will be enrolled into this 5-year non-residential,
multicentre study across 10 cities in Germany. They will be assessed at 10 timepoints with 6 month intervals during
which inclusion criteria will be reassessed and spent cigarette filter tips, saliva and 24 h urine samples will be
collected. These samples will be used to determine average daily cigarette consumption, estimate mouth-level
exposure to tar and nicotine and measure selected biomarkers of exposure, respectively. Spontaneous changes in
subjects’ preferred cigarette products and any consequent change in tar or nicotine yield will be monitored.
Subjects will be required to complete questionnaires on quality of life, smoking behaviours, smoking-related sensory
attributes and recent life changes.
Discussion: The planned study is anticipated to contribute to understanding smokers’ behaviours and their
consequent exposure to smoke constituents. It will also allow assessment of compensatory changes in their
behaviour following spontaneous switching of cigarette product smoked. Data from this study are expected to
provide insights into study design and conduct for non-clinical assessment of smokers’ exposure as part of post
marketing surveillance programmes.
Trial registration: Current Controlled Trials Database reference ISRCTN95019245.
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The long-term risks associated with cigarette smoking,
particularly cancer [1,2], cardiovascular disease [3] and
chronic obstructive pulmonary disease [4], are well estab-
lished. Few longitudinal studies, however, have assessed
spontaneous changes in smoking behaviour, and especially
whether a smoker’s nicotine uptake remains constant or
changes over time. Studies in adult smokers have shown
stable values for cigarette consumption and concentra-
tions of carboxyhaemoglobin (a biomarker for exposure to
carbon monoxide) over periods of several months when
smoking the same product [5-7].
Previous longitudinal studies of spontaneous product
switching
A small number of longitudinal studies have investigated
the effects of spontaneous product switching on smok-
ing behaviour [8-12] and the extent of compensatory
smoking behaviour. Compensation occurs when a
smoker changes their smoking behaviour in some way,
for example, puff volume, frequency or the number of
cigarettes smoked, in response to smoking a cigarette of
higher or lower smoke yield. Complete compensation
occurs when a smoker maintains their intake following a
change, no compensation results in a change that is pro-
portional to the change in product yield, and incomplete
compensation describes changes between these two ex-
tremes [13]. In a study in the USA, conducted by the
American Cancer Society between 1959 and 1972 on
changes in cigarette consumption in relation to changes
in tar and nicotine yield, data from 28,561 male smokers
were reported [8]. By the end of the study, 16,991 (59%)
smokers had changed to cigarettes with lower tar and
nicotine yields than at the start of the study, 8,190 (29%)
had not changed, and 3,380 (12%) had changed to ciga-
rettes with higher yields. Among smokers who had
switched to cigarettes with increased tar and nicotine
yields, 29% had also increased the number of cigarettes
they smoked per day, while 39% had decreased the num-
ber smoked. Likewise, although 32% of smokers who
had switched to lower tar and nicotine products smoked
more cigarettes per day, 34% smoked fewer. The data
suggest that changes in cigarette consumption were not
related to smokers changing to cigarettes of higher or
lower tar and nicotine yields, though the yields of tar
and nicotine in the cigarettes smoked during this period
would have been significantly higher than those typically
seen today in most countries.
The effects of changing to lower tar yield cigarettes
was investigated over a period of 13 years (1971–1984)
in nearly 600 male smokers [9]. Average cigarette con-
sumption reduced over the study period, but to a lesser
extent in smokers who had changed to lower tar ciga-
rettes than in those who had not. At the 1984 follow-up,similar amounts of urinary nicotine metabolites were ex-
creted by smokers who had and had not changed to
lower tar cigarettes at data collection, which suggests
compensatory smoking behaviour following switching.
In a study of the effects of spontaneous switching on
nicotine and carbon monoxide exposure in 203 smokers,
a reduction in cigarette consumption of 6.6 cigarettes
per day was observed in smokers who changed spontan-
eously to lower nicotine yield cigarettes, with smaller re-
ductions in consumption for smokers who had not
changed product or who had changed to higher nicotine
yield cigarettes (1.9 and 1.8 fewer cigarettes, respectively)
[10]. For the smokers who changed to lower nicotine
yield cigarettes, absolute plasma cotinine levels were re-
duced, however, plasma cotinine levels per cigarette were
little altered, which suggests an increase in smoking in-
tensity. In a longitudinal study in South Germany, 41
smokers changed their cigarette during the study, 13 of
whom changed to a lower tar product [11]. The extent
of the reductions in cotinine concentrations suggested
55% compensation.
In 2002–2005, Muhammad-Kah and colleagues assessed
spontaneous product switching in 2,542 smokers in the
USA, of whom 68 switched to higher tar products and 23
switched to lower tar products, with subsequent decreases
of two cigarettes and increases of two cigarettes per day,
respectively [12]. Substantial variability and insufficient
power to detect significant differences in biomarkers of
exposure, however, led to no definitive conclusions being
reported.
Since 2004, in the European Union the maximum per-
mitted tar and nicotine yields have been 10 mg and 1 mg
per cigarette, respectively, measured using International
Organization for Standardization (ISO) methods [14]. Fol-
lowing the introduction of these regulations, long-term
changes in consumption [15], nicotine uptake, exposure
to smoke toxicants and the effects of switching to ciga-
rettes of lower yields are unclear. The World Health
Organization (WHO) Study Group on Tobacco Product
Regulation (TobReg) identified a number of research areas
as being key to enhancing this knowledge [16], which in-
clude assessment of whether an increase or decrease in
nicotine content per unit (e.g. per cigarette) would be
beneficial to a population’s health and investigation of
contents and design features that might reduce toxicity,
consumer appeal and/or the potential for dependency. In
2009, the US Food and Drug Administration was given
jurisdiction over tobacco products via the US Family
Smoking Prevention and Tobacco Control Act, and in
2012 issued draft guidance on the key areas to be investi-
gated in making marketing applications for modified-risk
tobacco products, which includes the requirement for
post-market surveillance studies [17]. The FDA is also
considering product standards, which could involve the
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and nicotine.
Study objectives
We plan to undertake a longitudinal study to address
some of the TobReg research aims [16], to provide in-
sights into appropriate study designs for undertaking
post marketing surveillance programmes. We will study
the effects of spontaneous product switching over a 5
year period on the following features of smoking behav-
iour: average daily cigarette consumption, mouth-level
exposure (MLE) to nicotine and tar [18]; uptake of nico-
tine, assessed by measurement of urinary and salivary
biomarkers of exposure; and exposure to the smoke
toxicant 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
([NNK] a tobacco-specific nitrosamine) through the
measurement of metabolites in urine. Secondary objec-
tives are to assess any compensatory smoking behaviour
and changes in quality of life and sensory perception fol-
lowing spontaneous product switching.
Methods/design
Study design
The study will be performed in Germany over 5 years
and will involve 10 non-residential study centres. The
study will comprise 10 timepoints over the 5-year
period, each of 6 months’ duration. Each timepoint will
include a 12-day fieldwork period consisting of three
clinical visits separated by ambulatory periods (Figure 1,
Table 1) and telephone based interviews between the
fieldwork periods.
The protocol and the informed consent form have
been reviewed and approved by the Ethics Committee ofFigure 1 Study activities during fieldwork periods.the Bavarian State of Chamber of Physicians (Ethik-kom-
mission der Bayerischen Landesärztekammer), Munich,
Germany (Ethics Committee Number 08036) as the cen-
tral voting ethics committee for the study. Approval was
given by all local ethics committees relevant to the site in-
vestigators (Sächsische Landesärztekammer, Ärztekammer
Nordrhein, Landesärztekammer Baden-Württemburg,
Ärztekammer Hamburg, Ärztekammer Berlin). The prin-
cipal investigator or designated investigators will ensure
that subjects are provided with oral and written infor-
mation regarding the study, associated activities and
storage of data and samples. Subjects will be required to
read, sign and date informed consent forms before
enrolment in the study. The study will be conducted by
an independent contract research organisation (CRO),
Harrison Clinical Research Deutschland GmbH, Munich,
Germany, in accordance with the ethics principles of
the Declaration of Helsinki [19] and the International
Conference on Harmonisation Guidelines for Good
Clinical Practice [20]. Subjects will be compensated for
the inconvenience and effort in participation in the




Male and female adult smokers of Lucky Strike Red King
Size cigarettes (LSR) (ISO yields 10 mg tar/cigarette and
0.8 mg nicotine/cigarette) will be eligible. Recruitment
of subjects will be undertaken by a market research
agency (MRA), Ipsos Operations GmbH, Hamburg,
Germany. Potential subjects will be selected from people
approached in the streets in the vicinity of shops selling
Table 1 Study activities per timepoint
Day 1 Visit 1 Days 2 to 8 Day 9 Visit 2 Day 10 Day 11 Day 12 Visit 3 Call 1 Call 2 Call 3
Informed consenta X






Materials provided to Subject
Urine collection bottles X
Aluminium containers for butt collection X X
Issue of cigarettes for 1 day X
Filter cutters with integrated tin X
Sensory questionnaire X
Subject activities
Usual subject environment X X X X X X
Smoke own supply of cigarettes X X X X X X X X
Collection of cigarette butts X X X
Collection of part-filter tips X
Start 24 hour urine collection X
End 24 hour urine collection X
Smoke provided cigarettes X
Complete questionnaires X X X X







aInformed Consent will be taken at visit 1, first fieldwork period only or if updated.
bHeight and ECG will be measured at visit 1, first fieldwork period only.
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those who respond to local newspaper advertisements.
Inclusion criteria
Subjects will be required to satisfy the following inclu-
sion criteria: age 21–64 years at the time of signing the
informed consent; female subjects must not be pregnant
or lactating at the time of enrolment; be in good health,
as determined by medical history, baseline 12-lead elec-
trocardiography (ECG), lung-function tests and meas-
urement of blood pressure; smoke eight or more LSR
cigarettes per day and have done so for at least 6
months at the time of enrolment; willingness to provide
written informed consent to participate in the study;
and willingness to purchase cigarettes for personal use.Continued eligibility for inclusion according to these
criteria will be reassessed at each timepoint during the
study.
Exclusion criteria
Subjects who fulfil any of the following criteria will not
be enrolled: having an existing chronic disease, such as
asthma, cardiovascular disease, chronic obstructive pul-
monary disease, or a history of lung cancer or any other
tobacco-related disease, as determined by the principal
investigator and/or site investigator; participation in an-
other study of smoking habits in the previous 6 months;
trying to stop smoking or considering doing so in the
next 2 months; a candidate or an immediate family
member working in public relations or advertising for
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of tobacco goods; consumption of tobacco products
other than factory-made cigarettes available on the German
market (e.g. products that do not comply with the
German Tobacco Ordinance Act, Tabakverordnung
[TVO], smokeless tobacco products, and non-filtered
products such as cigars or pipes); and candidates who in
the opinion of the principal investigator and/or site in-
vestigator should not participate in the study. These ex-
clusion criteria will be reassessed at each timepoint.
Subject withdrawals
After enrolment subjects are free to withdraw from the
study at any time. In addition, the principal investigator
and/or site investigator may decide to withdraw a sub-
ject if a protocol violation is suspected. The date and
reasons for the withdrawal will be clearly stated in the
subject’s case report form. No subjects will be withdrawn
for not attending scheduled visits or calls during the
fieldwork periods or timepoint, provided they can be
contacted later and can provide a reason for non-
attendance. Otherwise, they will be entered into the lost-
to-follow-up process. Withdrawn subjects will not be
replaced.
Fieldwork periods
Fieldwork periods will cover the first 12 days of every
timepoint (Figure 1). Subjects will visit the study centres
three times during these 12 days (visits 1, 2 and 3), on
days 1, 9 and 12. Day 1 of the first fieldwork visit will be
used to assess the eligibility of subjects according to the
inclusion and exclusion criteria and to assign each sub-
ject with a unique study code. The subjects’ identifica-
tion and study codes will be checked at each visit.
During visit 1, medical history and demographic data
will be updated, and blood pressure, spirometry, weight,
height and ECG (latter two, first fieldwork period only)
will be assessed. Subjects will be given aluminium con-
tainers for daily collection of cigarette butts from all cig-
arettes smoked on days 2–9 and instructed verbally how
to collect them. Interviewer-led questionnaires on smok-
ing behaviour will be completed.
During visit 2, the butts from days 2–8 will be counted
to calculate average daily consumption and cigarette
brands will be checked. Aluminium containers will be
supplied for collection of cigarette butts on day 10, along
with a filter cutter/collector, and instructions for the col-
lection of part-filters for filter analysis from cigarettes
smoked on day 11. Polyethylene containers, also for use
on day 11, will be provided with verbal and written in-
structions for 24 h urine collection along with a report
sheet on which to record any medications taken during
this period. A 1-day supply of the subjects’ current ciga-
rettes will be provided for smoking on day 11. A sensoryevaluation questionnaire will be provided for self-
completion during day 11.
During visit 3, the used cigarette butts collected on days
9 and 10, the 24 h urine sample and cigarette part-filter
samples from day 11 and the self-completed sensory ques-
tionnaires will be collected. Saliva samples will be taken
under the supervision of a study nurse, for analysis of the
nicotine metabolites cotinine and trans-3′-hydroxycoti-
nine (OH-cotinine). A self-reported questionnaire on re-
cent life changes and interviewer-led questionnaires on
smoking behaviour and quality of life will be completed.
Study staff will also contact participants by telephone
four times during each timepoint, at approximately 2 and
4 months after the last fieldwork visit (calls 1 and 2), 1
week before the next fieldwork period (call 3) and on day
10 of fieldwork periods (call 4). During telephone contact,
the following activities will take place: calls 1 and 2 will be
interviews with subjects to verify they still meet the ori-
ginal non-medical inclusion criteria and to record which
cigarette products are currently being smoked, reasons for
any change in current cigarette product smoked since the
previous timepoint and self-reported daily consumption;
call 3 will be to remind subjects of their visit 1 appoint-
ment and determine whether they have changed their
cigarette product; call 4 will be to remind subjects to col-
lect part-filter tips and urine on day 11.
Study procedures
ECG assessment
During visit 1 of the first fieldwork period only, subjects
will undergo 12-lead resting ECG with a 10 s rhythm.
Subjects will be supine for at least 5 min before the test.
The ECG will be performed, documented and assessed
by a physician. Any subject with an abnormal rhythm or
trace shape on ECG will be excluded from the study and
advised to consult a cardiologist. ECGs may be under-
taken in other fieldwork periods if a subject reports rele-
vant symptoms, but he or she will be advised to consult
a cardiologist and a copy of any follow up report will be
retained.
Blood pressure and pulse rate assessments
Supine blood pressure and pulse rate will be measured
during visit 1 of the first fieldwork visit. Subjects will be
supine for at least 5 min before assessments. During visit
1 of all subsequent fieldwork periods, blood pressure
and pulse rate measurements will be taken with subjects
in the sitting position. Blood pressure assessment will
also be performed at other times if judged to be clinic-
ally appropriate by the study staff.
Spirometry
Spirometry will be used to measure forced expiratory vol-
ume in 1 s (FEV1) as evidence of changes in pulmonary
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tests will be performed at visit 1 of all fieldwork periods.
All subjects will stand during lung-function measure-
ments and the best of three technically acceptable at-
tempts will be taken as the true measure of lung function
for each timepoint. At least one other attempt must give a
result within 5% of the best value for the average to be
valid. If necessary, measurements will be repeated until
two attempts within 5% of each other are obtained. If a
subject shows signs of fatigue, testing will be halted and
will only recommence at the physician’s discretion.
Cigarette butt collection
In every fieldwork period, subjects will be provided with
labelled aluminium containers, and instructed to collect
butts from all cigarettes smoked on days 2–9 in those
aluminium containers provided at visit 1, and the butts
from cigarettes smoked on day 10 in the containers pro-
vided at visit 2.
During visit 2, the collected cigarette butts from days
2–8 will be counted at the study centres to calculate
average daily cigarette consumption and identify the
brands smoked, where possible. After counting, the butts
will be discarded. Subjects who have deviated from their
normal cigarette consumption (defined as an increase or
decrease in consumption on ≥1 day by more than 25%
of the average daily consumption from days 2–8) will
complete an interviewer-led questionnaire to identify the
reasons for the deviation. At visit 3, the collected butts
for days 9 and 10 will be counted in the same manner.
Smoking and part-filter collection
On all days during the study, except day 11 of the field-
work periods, subjects will purchase and smoke their
own cigarettes. On day 9 of every fieldwork period, ciga-
rettes that match each smoker’s current product will be
provided in sufficient quantity to match average daily
consumption, along with a labelled filter cutter with in-
tegrated collection tin. The subjects will be requested to
smoke only these cigarettes on day 11, from the first to
the final cigarette of the day, and to use no other
nicotine-containing products during this 24 h period.
Subjects will be instructed to smoke the provided ciga-
rettes as usual and to cut off and collect 10 mm mouth
end sections of the filter tips from every cigarette
smoked that day. To minimise the possible influence of
changes in smoking behaviour caused by social circum-
stances and environment, fieldwork periods will be
scheduled to ensure that the collection of filter tips will
occur only on working days. The number of filter tips in
the filter cutter will be counted on day 12.
Filter tips must meet the quality guidelines of the
sponsor (i.e. not crushed or containing ash and of ap-
proximate correct length). If they are not of adequatequality, subjects will collect them again on the next
available working day, along with repeating the 24 h
urine collection. The collected cigarette filters will be
stored at room temperature pending dispatch to the
sponsor for analysis of tar and nicotine content. These
data will be compared with calibration curves from a
range of machine smoking regimes, where the nicotine
and tar yields and filter nicotine and tar contents are
known and the MLE to nicotine and tar per cigarette
calculated [21]. Daily MLE estimates will be calculated
by multiplying the per-cigarette values by the number of
cigarettes consumed on day 11 of the fieldwork periods.
Urine collection and processing
Urine will be collected into standard-weight polyethyl-
ene containers. The 24 h collection period will always be
on working days to minimise the possible influences of
social circumstances and environment on smoking be-
haviour. The collection period will commence after the
first morning void, which will be discarded, and will
continue throughout day 11 and include the first morn-
ing void on day 12. The times of the first void, first col-
lection and last collection will be recorded by subjects
on the provided report sheets. During each 24 h collec-
tion period, the containers will be stored in a cool bag
with two frozen cooling elements.
Subjects will document on the provided report sheets
any medications taken during the 24 h urine collection
period. The bulk urine for each subject will be frozen
within 15 min of receipt and transported to the CRO,
where it will be stored at approximately –20°C until ana-
lysis, when it will be thawed and the weight recorded. A
nominal value for specific gravity (1.018) will be used to
calculate urine volume [22].
After the bulk urine has completely thawed, aliquots
will be transferred into suitably labelled polypropylene
tubes and stored at approximately –20°C pending
dispatch for analysis by ABF GmbH, Munich, Germany,
and long-term storage at Covance, Leeds, UK.
Urine samples will be analysed for the concentration of
nicotine and five main metabolites (cotinine, OH-cotinine,
nicotine-N-glucuronide, cotinine-N-glucuronide and trans-
3′-hydroxycotinine-O-glucuronide) and the metabolites
of NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
(NNAL) and NNAL-glucuronides (total NNAL). Cre-
atinine concentration will be determined to provide an
indication of urine collection compliance.
Saliva collection
On visit 3 of each fieldwork period, saliva samples will be
collected after 15:00 h from all subjects, for measurement
of the nicotine metabolites cotinine and OH-cotinine.
Samples will be collected with Salivettes (Sarstedt,
Nuembrecht, Germany). Subjects will be asked to place
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with a slight chewing action to allow for saturation with
saliva over a 2 min period. Within 15 min of collection
the samples will be frozen and stored at approximately –
20°C, pending dispatch for analysis.
Monitoring of changes in cigarette consumption
Checks on whether each smoker has changed their main
cigarette product will be carried out at calls 1, 2 and 3 of
each timepoint. The products reported by the subjects
during call 2 will be obtained by the sponsor for supply at
the next fieldwork period. Call 3 will identify any changes
in a subject’s cigarette product smoked, one week before
the fieldwork period. Change to cigarettes with a lower
ISO tar yield compared to those smoked at baseline (e.g.
from 10 mg to 6 mg), a higher ISO tar yield (e.g. from 6
mg to 10 mg) and to a different cigarette with the same
ISO tar yield (e.g. one 10 mg ISO tar product to another
10 mg ISO tar product) will be permitted. Subjects will be
considered no longer eligible if they change their smok-
ing habits in any of the following ways: change to smok-
ing cigarettes that are not TVO compliant; change to
smoking non-filtered products; change to smoking self-
rolled (roll your own) cigarettes or self-filled “stix”
(make your own) cigarettes, with or without filters;
change to using chewing tobacco or other smokeless to-
bacco products; and use of nicotine-replacement ther-
apy or decision to quit smoking.
The MRA will maintain all information regarding
switches in products and smoking behaviour.
Completion of questionnaires
On day 1 of visit 1 of every fieldwork period, subjects
will complete an interviewer-led electronic questionnaire
on smoking behaviour, including the Fagerström Test
for Nicotine Dependence [23]. Questionnaires about de-
viation from normal cigarette consumption will be com-
pleted during visit 2 of fieldwork periods, on day 9, and
questionnaires on sensory attributes will be provided for
self-completion at home on day 11. These will be
returned on day 12 at visit 3. During visit 3, subjects will
also be required to self-complete the Recent Life
Changes questionnaire [24] and the interviewer-led SF-
36v2 Quality of Life questionnaire [25]. The responses
to the self-completed questionnaires will be entered into
an electronic data capture system at the study centres by
study personnel.
Lost to follow-up
Subjects will be permitted to miss whole timepoints pro-
vided they are contactable and can give valid reasons for
doing so. Subjects who cannot be contacted during
scheduled events (visits or calls) will enter the “lost-to-
follow-up” process. The process starts with a telephonecall, followed up by a second call two weeks later, if the
subject makes no response. If there is still no response
from the subject, he or she will be sent a letter by fax or
e-mail if contact information is available. The final step
in this process is that a registered letter will be sent to
the subject. If the subject responds to any contact, the
process will be stopped. Otherwise, the subject will be
withdrawn from the study by the principal investigator.
Sample size and power calculations
It is expected that the subjects will separate into three
groups during the study: subjects who do not change
product from the original 10 mg ISO tar product
throughout the study; those who change to cigarettes
with ISO tar yields of 7 mg or lower (down-switchers);
and those who change to cigarettes with ISO tar yields
of 8–10 mg (side-switchers). A fourth group is possible
that will include subjects who down-switch but subse-
quently change back to cigarettes of higher tar yields
(up-switchers). Subjects cannot up-switch from the ori-
ginal 10 mg ISO tar product due to the upper limit of 10
mg ISO tar for cigarettes sold in the EU [14]. Analysis of
biomarkers of exposure in sub-populations of smokers
and non-smokers in Germany indicated that differences
of 20% between the subject groups for each respective
biomarker would yield results significant at an alpha
level of 0.05 where group sizes were greater than n = 50
[26]. Power and sample size calculations were also used
to determine thresholds required to detect significant
differences between subject groups. These calculations
showed that to achieve a power of 80%, a sample size of
51 will be required to detect differences of 2 mg in MLE
to tar between subject groups [26]. To achieve a mini-
mum of 51 subjects in each of the three subject groups
over multiple timepoints and taking account of predicted
product switching rates (3.7% down-switching and 10%
side-switching), and allowing for an annual reduction of
20.4% (based on a combination of subject withdrawal
and attrition from the study and an annual quitting
smoking rate of 12.4%), it will be necessary to recruit
1000 subjects. Based on the predicted annual reduction
of 20.4%, it is predicted that 319 subjects will complete
the study.
Statistical analysis
The statistical analyses to address the primary and sec-
ondary objectives will be performed on the final per
protocol population. Data will be tested for normality
and homogeneity of the variance and, if appropriate,
data will be transformed to try to satisfy analysis of vari-
ance (ANOVA) assumptions. If normality approximation
cannot be achieved, non-parametric methods may be
employed. A linear mixed model will be used to assess
group changes over time for all MLE, biomarkers of
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will include fixed effects due to subject group (non-
switcher, down-switcher or side-switcher), timepoint,
gender, subject group*timepoint interaction and age as a
covariate. The interaction term will be removed from
the model if not statistically significant. Data from the
first timepoint will be used to account for possible sub-
ject differences at the start of the study. Repeated mea-
sures ANOVA will be performed to account for the
correlation over time within each subject.
Established procedures will be used to determine the
extent of any compensation effect, as a result of subjects
switching products. These procedures calculate compen-
sation indices on the basis of machine-smoked yields
and exposure data [13,27].
A detailed statistical analysis plan of the methodology
to be used will be prepared before the database closure.
Discussion
The planned study is the first longitudinal study of
smokers’ exposure to current cigarette products in over
20 years and has been designed to contribute to the un-
derstanding of exposure of smokers over the long-term to
cigarette smoke and selected constituents and any changes
in consumption. The effects of switching to cigarettes of
different tar and nicotine yield have been extensively stud-
ied, yet very few studies have considered spontaneous
product switching, where the smokers have chosen their
new product. Understanding of exposure to the constitu-
ents of tobacco smoke after smokers change products will
be increased and whether smokers make any compensa-
tory changes to their smoking behaviour assessed. The
data may also show whether changing to products with
lower tar and nicotine yields would have any benefits for
the smoker with respect to quality of life.
Data from this study are expected to contribute to the
development and long-term assessment of tobacco prod-
ucts with reduced contents of harmful substances fol-
lowing their introduction on to the market, as part of
post-marketing surveillance programmes [16,17,28,29].
In the next few years, new methods to analyse bio-
markers of exposure to tobacco products are expected
to be available. The use of these new methods on sam-
ples in this study could greatly increase the amount of
knowledge gained. The results of this study will be pub-
lished in peer-reviewed scientific journals.
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